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AbstrACt
Objectives Large differences exist in the burden of 
cardiovascular disease (CVD) between Russia and Western 
European countries including Norway. Obesity prevalence 
may contribute to the differences. We investigated whether 
difference in the level of adiposity, assessed using body 
mass index and waist- to- hip ratio(WHR), could explain 
intercountry differences in the burden of carotid plaque, a 
measure of atherosclerosis, in the populations.
Design Cross- sectional analysis. Logistic and linear 
regression models were used.
setting We used population- based cross- sectional Know 
Your Heart (KYH) study in Russia and the Tromsø 7 study 
(Tromsø 7) in Norway.
Participants 3262 and 1800 men and women aged 
40–69 years in KYH and Tromsø 7, respectively.
Primary and secondary outcome The presence 
of carotid plaques and plaque score assessed using 
ultrasound.
results The presence of carotid plaques and plaque score 
were higher in KYH than Tromsø 7 regardless of age group 
and sex. A positive association between carotid plaque 
burden and adiposity was found (OR of having at least one 
plaque per SD in WHR 1.18 (95% CI 1.06 to 1.31) for men; 
1.15 (1.06 to 1.25) for women)) adjusted for age, smoking 
and education in a pooled analysis of the two studies. 
There was little evidence of the interaction between study 
and adiposity. These effects did not differ between the two 
studies. However, neither adiposity nor CVD risk factors 
(smoking, systolic blood pressure, cholesterol, glycosylated 
haemoglobin) explained the higher carotid plaque burden 
in KYH compared with Tromsø 7.
Conclusion Adiposity, especially abdominal adiposity, 
is a risk factor for carotid plaque in Russia and Norway, 
although neither adiposity nor established CVD risk 
factors explained the higher plaque burden in Russia. 
To reduce the CVD burden in Russia, beyond prevention 
and treatment of adiposity, further research is required 
to understand why Russia has a high burden of 
atherosclerosis.
IntrODuCtIOn
The mortality rate from cardiovascular 
disease (CVD) has been decreasing for many 
years in Western Europe, and more recently, 
in Eastern Europe.1 However, rates vary 
substantially between countries, with Russia 
having one of the highest CVD mortality 
rates,2 although it has been declining since 
2005.3 In 2012–2016, the CVD mortality rate 
at working ages in Russia was eight times 
higher than that in Norway.4 These prema-
ture deaths contribute to the relatively low life 
expectancy for such an industrialised country. 
However, the reasons for this very high CVD 
burden in Russia remain unclear.4 It appears 
that the differences in conventional CVD risk 
factors such as smoking, blood pressure and 
cholesterol levels do not explain this differ-
ence well.5 6
The increase in obesity over the past 
decades is a growing concern worldwide, 
including in Russia and countries of Western 
strengths and limitations of this study
 ► This is the first study to compare adiposity level, ca-
rotid plaque burden and its association with adipos-
ity between Russia and Western European country 
with low cardiovascular disease mortality.
 ► The use of two substantial population- based stud-
ies with similar study period and study protocols 
enabled us to make a direct comparison of two 
populations.
 ► Waist circumference was measured at different 
measurement sites between the two studies.
 ► We did not assess visceral adiposity or body 
composition.
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Europe,7 and has an effect on mortality levels.8 In addi-
tion to general obesity, however, the extent of abdominal 
obesity is likely to be important as there is evidence that it 
is more strongly associated with CVD events than general 
adiposity assessed using body mass index (BMI).9–11 
However, data on population levels of abdominal obesity 
(such as waist- to- hip ratio (WHR)) is far less common 
than for BMI, in Russia as well as in other countries. To 
the best of our knowledge, the contribution of general 
or abdominal obesity to the gap in CVD burden between 
Russia and Western European countries has not been 
investigated in spite of increasing importance of obesity 
as a CVD risk factor.
Carotid plaque, representing an advanced stage of 
atherosclerosis, is predictive of future CVD events.12 
Carotid atherosclerosis may be easily and reliably detected 
using an ultrasound examination making carotid plaque 
a good surrogate marker of atherosclerotic CVD burden 
in large- scale epidemiological studies. Our previous study 
using Tromsø Study fifth survey has shown that abdom-
inal adiposity was more closely associated with carotid 
plaque burden than BMI.13 Furthermore, WHR showed 
the larger effect size than waist circumference (WC) and 
waist to height ratio.
We used data from two studies from general popula-
tions with very different CVD mortality in Europe: Know 
Your Heart (KYH) study in Russia and Tromsø Study 
seventh survey (Tromsø 7) in Norway. Our aims were: (1) 
to compare general and abdominal adiposity levels, repre-
sented by BMI and WHR, respectively, and the burden of 
carotid plaque in Russia with those in Norway, a low CVD 
mortality country; (2) to investigate the association of 
BMI or WHR with carotid plaque in both populations and 
(3) to investigate whether BMI or WHR or other factors 
can explain difference in carotid plaque burden between 
the two populations.
MethODs
study design and participants
We used data from two studies; the KYH study from Russia 
and the Tromsø 7 study from Norway. Researchers from 
the two studies worked together at the design stage to 
align aspects of the study protocols used, including the 
detailed standard operating procedures for carotid ultra-
sound examinations as described elsewhere.4 14 15
KYH is a population- based cross- sectional study of 
4500 women and men aged 35–69 years conducted 
between 2015 and 2017 in two Russian cities: Novosi-
birsk and Arkhangelsk. The details of KYH have been 
described elsewhere.4 Briefly, participants were recruited 
from a random sample of the population stratified by 
age and gender, derived from the list of the Territorial 
Health Insurance Funds. Trained interviewers visited 
the addresses on the list and identified residents of the 
target age and sex. Information on sociodemographic 
characteristics, CVD risk factors and medical history was 
collected using structured questionnaires completed on 
tablet computers. At the end of the interview, partici-
pants were invited to have a comprehensive examina-
tion including anthropometric measurement, blood 
sampling, and carotid ultrasound 1 or 2 weeks later. 
Response rates for initial interview were 53% and 27% 
in Arkhangelsk and Novosibirsk, respectively. Of those 
interviewed 89% attended the subsequent medical exam-
ination. All participants of the medical examination 
provided signed informed consent.
The Tromsø Study is an ongoing population- based 
study in Tromsø municipality, North Norway and consists 
of seven surveys from 1974 to 2016.16 In the seventh wave 
(Tromsø 7), all residents in Tromsø aged 40 years and 
older were invited to participate. The questionnaires 
were completed, a brief physical examination was carried 
out and biological samples were taken. A random sample, 
including previous participants, was invited to a second 
visit to undergo more comprehensive medical examina-
tions. A total of 21 083 attended the first visit and the 
response rate was 65%. A total of 4153 participants were 
invited to a carotid ultrasound examination and 2974 
(71.6%) attended.
In the two studies, participants aged between 40 and 
69 years (n=5782) were eligible for the present study. We 
excluded participants with missing data on all adiposity 
measures (n=42), and potential confounders and medi-
ators (n=678), leaving 3262 participants from KYH (57% 
women) and 1800 from Tromsø 7 (55% women) for the 
analyses.
Assessment of anthropometric measures and other CVD risk 
factors
In both studies, height and weight were assessed by trained 
staff using standard methods (see online supplementary 
material). BMI was calculated by dividing weight in kilo-
grams by squared height in metres. WC was measured at a 
different site in the two studies: in KYH WC was measured 
at the narrowest part of the trunk to the nearest milli-
metre using a tape measure while in Tromsø 7 WC was 
measured at the level of the umbilicus. Hip circumfer-
ence was measured at the widest part in both studies. To 
ensure WC was comparable between the two studies, WC 
in Tromsø 7 was converted to the narrowest waist using a 
conversion equation by Mason and Katzmarzyk.17 Among 
anthropometric measures of abdominal adiposity WHR 
was selected because it has been found to be strongly asso-
ciated with CVD events.10 11 18
Information on age (5- year categories), smoking 
(current smoker, ex- smoker, never- smoker), educa-
tional attainment (higher education: yes/no) and 
medical history of diabetes mellitus (DM) (yes/no) were 
collected through face- to- face interview in KYH and self- 
administered questionnaire in Tromsø 7. The assessment 
of systolic blood pressure (SBP) and other laboratory 
data are described elsewhere (see online supplementary 
material).4
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ultrasound examination
Technical details of the examination protocols have been 
described elsewhere.4 14 15 Briefly, both carotid arteries 
were scanned for carotid plaques in the common carotid 
artery (CCA), bifurcation and internal carotid artery 
(ICA) using a Vivid Q (GE Health care) with 6~13 MHz 
linear transducers in KYH and Vivid 7 (GE Health care) 
with a linear 12 MHz transducer in Tromsø 7 (see online 
supplementary material). Carotid plaque was defined 
according to the Mannheim Consensus as a focal struc-
ture encroaching into the arterial lumen by at least 
0.5 mm, or having a thickness ≥50% greater than the 
surrounding intima–media thickness (IMT), or IMT >1.5 
mm as measured from the media–adventitia interface to 
the intima–lumen interface.19
To evaluate the burden of carotid plaque, we created 
a cumulative plaque score by assigning a score of one 
for the presence of one or more plaques in each of the 
six carotid segments (CCA, bifurcation and ICA of each 
carotid artery) with a maximum possible score of 6 for 
each individual.
statistical methods
Analyses were conducted stratifying by sex a priori. Two 
outcome measures were used: the presence of plaques as 
a binary outcome and plaque score. As exposures, BMI 
and WHR were used to represent general and abdominal 
adiposity, respectively. To enable direct comparison of the 
magnitude of the effects of BMI and WHR, sex- specific 
adiposity z- scores standardised to Tromsø 7 participants 
were created by subtracting the mean and dividing by the 
SD of each measure in Tromsø 7.
Variables included in the model were selected from 
established CVD risk factors.2 20 Age, smoking and educa-
tion were considered a priori confounders while SBP, 
high- density lipoprotein cholesterol, low- density lipopro-
tein cholesterol, glycosylated haemoglobin (HbA1c) and 
medical history of DM were considered as potential medi-
ators. Sex- specific linear and logistic regression models 
were used to investigate the associations of each adiposity 
with plaque score and presence of plaques respectively. A 
series of models were fitted that were specific to each sex 
and study (four in all). Model 1 adjusted for age (5- year 
age groups). Model 2, our main model to elucidate the 
association between adiposity and plaque burden, further 
adjusted for potential confounders. Model 3 further 
adjusted for potential mediators to see to what extent 
the association was mediated by these factors. These anal-
yses were conducted using the data from each study and 
the pooled data from the two studies after checking for 
interaction with study. This was done by adding an inter-
action term between study and adiposity using pooled 
data: testing for statistical significance using likelihood 
ratio tests for logistic regression and Wald tests for linear 
regression.
Finally, to estimate the difference in plaque burden 
between the two studies, we applied a similar set of 
models as already described to the pooled data using 
a binary indicator for study. The associations between 
each study and plaque burden (the presence of plaques, 
plaque score) were estimated using logistic and linear 
regression, respectively. To look at adjusted difference 
in plaque burden between the two studies, three similar 
models adjusted for age, confounders and mediators, 
were applied without adjustment for adiposity. We then 
separately added each adiposity measure to these models 
to estimate the effect of adiposity on between- study differ-
ence in carotid plaque burden.
STATA V.15 (StataCorp) was used for all the analyses.
Patient and public involvement
This study was part of the International Project on 
Cardiovascular Disease in Russia (IPCDR). IPCDR had an 
important Public Engagement component as described 
on the project website (https://knowyourheart.science/). 
This involved a wide range of activities that ranged from 
television programmes on the KYH study, focus groups 
and publication of popular articles on CVD in the Russian 
media. The Heart to Heart comparisons of Norway with 
Russia have received media coverage in the Norwegian 
media, and the Tromsø 7 study itself involved extensive 
publicity engagement with the citizens of the city of 
Tromsø. Members of the general public were not involved 
in the design or the study or its scientific aims.
results
baseline characteristics of participants
Table 1 shows participants’ baseline characteristics. The 
age- adjusted prevalence of current smoking in men 
was much higher in KYH than Tromsø 7 but similar for 
women. However, female never smokers made up two- 
thirds in KYH but just over a third in Tromsø 7. Mean SBP 
was considerably higher in KYH than in Tromsø 7.
Adiposity
Both BMI and WHR were higher for women in KYH than 
those in Tromsø 7. Adiposity z- scores for BMI and WHR 
for the KYH women standardised to the Tromsø 7 popu-
lation adjusted for age were 0.58 (95% CI 0.49 to 0.68) 
and 0.84 (95% CI 0.76 to 0.92), respectively. However, 
adiposity did not differ between men in the two studies.
Prevalence of carotid plaques
The prevalence of carotid plaques and the mean plaque 
score increased with age in both women and men 
(table 2). The burden of plaques was consistently higher 
in KYH than Tromsø 7 in both sexes.
the association between carotid plaque burden and adiposity: 
a pooled analysis of the two studies
Table 3 shows the ORs for having at least one carotid 
plaque per 1SD increase in each adiposity measure by sex 
from the pooled analysis. We also analysed the two studies 
separately, but only presented the result from the pooled 
data based on the test of interaction described below. The 
two adiposity measures were not adjusted for each other. 
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versus T7 KYH Tromsø 7
Comparison† KYH 
versus T7
N 1389 811 1873 989
Age years 56 (48–63) 61 (52–66) 55 (48–63) 60 (52–65)
Anthropometric 
measure
Difference (95% CI) Difference (95% CI)
Height cm 174.7 (6.6) 177.9 (6.7) −3.9 (−4.4 to −3.3) 161.1 (6.3) 164.7 (6.3) −4.1 (−4.6 to −3.6)
Weight kg 84.5 (15.5) 87.5 (12.9) −3.6 (−4.9 to −2.3) 74.5 (16.1) 71.4 (12.9) 3.4 (2.3 to 4.6)
BMI kg/m2 27.6 (4.6) 27.7 (3.7) 0.0 (−0.3 to 0.4) 28.8 (6.2) 26.4 (4.7) 2.7 (2.3 to 3.1)
WHR‡ 0.95 (0.07) 0.95 (0.07) −0.00 (−0.00 to 0.01) 0.84 (0.08) 0.79 (0.07) 0.06 (0.05 to 0.06)
Potential 
confounders
OR (95% CI) OR (95% CI)
Never- smoker (%) 351 (25.3) 316 (39.0) (Ref) 1304 (69.6) 383 (38.7) (Ref)
Ex- smoker (%) 518 (37.3) 377 (46.5) 1.3 (1.1 to 1.7) 285 (15.2) 451 (45.6) 0.2 (0.1 to 0.2)
Current smoker 
(%)
520 (37.4) 118 (14.6) 4.0 (3.1 to 5.1) 284 (15.2) 155 (15.7) 0.5 (0.4 to 0.6)
Higher education 
(%)
478 (34.3) 388 (47.8) 0.6 (0.5 to 0.7) 701 (37.4) 495 (50.1) 0.5 (0.4 to 0.6)
Potential 
mediators
Difference (95% CI) Difference (95% CI)
SBP mm Hg 138.6 (19.9) 132.8 (17.9) 7.3 (5.6 to 8.9) 129.8 (19.6) 126.4 (19.4) 5.7 (4.3 to 7.2)
Total cholesterol 
mmol/L
5.38 (1.13) 5.42 (1.05) −0.06 (−0.16 to 0.04) 5.68 (1.17) 5.62 (1.04) 0.13 (0.04 to 0.21)
Triglycerides 
mmol/L
1.35 (0.95 to 
–1.92)
1.50 (1.00 to 
–2.10)
−0.05 (−0.15 to 0.06) 1.23 (0.89 to 
−1.77)
1.10 (0.80 to −0.60) 0.18 (0.11 to 0.26)
HDL cholesterol 
mmol/L
1.32 (0.33) 1.41 (0.39) −0.09 (−0.12 to −0.06) 1.55 (0.36) 1.78 (0.49) −0.24 (−0.27 to −0.20)
LDL cholesterol 
mmol/L
3.66 (0.90) 3.63 (0.99) 0.01 (-0.07 to 0.09) 3.80 (0.95) 3.60 (0.96) 0.27 (0.19 to 0.34)
HbA1c (%) 5.60 (0.84) 5.74 (0.57) −0.08 (−0.14 to −0.01) 5.57 (7.69) 5.67 (0.51) −0.04 (−0.09 to 0.01)
OR (95% CI) OR (95% CI)
Diabetes mellitus 
(%)
93 (6.7) 47 (5.8) 1.4 (1.0 to 2.1) 182 (9.7) 52 (5.3) 2.5 (1.8 to 3.5)
Data are presented as percentages for binary variables and as mean values (SD) continuous variables, except for age, triglycerides which are 
presented as median (IQR).
*Analyses were restricted to participants aged between 40 and 69 years with information on all covariates.
†All comparisons age adjusted.
‡WC in Tromsø 7 assessed at the level of the umbilicus was converted to the narrowest WC so that it can be comparable with WC in KYH. WHR in 
T7 are calculated using converted WC.
.BMI, body mass index; HbA1c, glycosylated haemoglobin; HDL, high- density lipoprotein; LDL, low- density lipoprotein; SBP, systolic blood pressure; 
WC, waist circumference; WHR, waist- to- hip ratio.
After adjustment for confounders (model 2), there was 
evidence of association between all adiposity measures 
and the presence of plaques except for BMI in women. 
WHR showed larger standardised ORs (women 1.15 95% 
CI 1.06 to 1.25, men 1.18 95% CI 1.06 to 1.31) than BMI. 
After further adjustment for cardiometabolic mediators 
(model 3), all ORs decreased substantially.
Table 4 shows the difference in plaque score per 1 SD 
increase in each adiposity measure. In women, adiposity 
was associated with an increase in plaque score. Again, 
WHR showed a larger effect size (increase per 1SD change 
0.109 95% CI 0.070 to 0.147) than BMI. Additional adjust-
ments for cardiometabolic mediators reduced both effect 
sizes substantially. For men, there was no evidence of an 
association of BMI and WHR with plaque score.
Tests for interaction between study and adiposity were 
not statistically significant except for the association 
between BMI and the presence of plaque in women 
and that between WHR and the plaque score in women, 
suggesting that there is little evidence that the association 
between adiposity and plaque burden differs between the 
two studies (online supplementary table 1, online supple-
mentary figure 1A, B).
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KYH versus T7* KYH Tromsø 7
Comparison 
KYH versus T7*
N 1389 811 1873 989
Prevalence n 
(%)
OR (95% CI) OR (95% CI)
All age 1050 (75.6) 499 (61.5) 3.2 (2.6 to 4.0) 1043 (55.7) 478 (48.3) 1.9 (1.6 to 2.3)
40–49 212/394 (53.8) 38/148 (25.7) 3.5 (2.3 to 5.4) 174/570 (30.5) 40/189 (21.2) 1.7 (1.1 to 2.5)
50–59 340/450 (75.6) 104/191 (54.5) 2.7 (1.9 to 4.0) 328/605 (54.2) 112/273 (41.0) 1.7 (1.3 to 2.3)







All age 1.9 (1.6) 1.2 (1.1) 1.0 (0.9 to 1.2) 1.1 (1.3) 0.8 (0.9) 0.5 (0.4 to 0.6)
40–49 1.0 (1.2) 0.3 (0.6) 0.6 (0.5 to 0.8) 0.5 (0.8) 0.3 (0.6) 0.2 (0.1 to 0.3)
50–59 1.8 (1.5) 0.9 (1.0) 0.9 (0.7 to 1.2) 1.0 (1.2) 0.6 (0.8) 0.4 (0.3 to 0.6)
60–69 2.7 (1.6) 1.5 (1.2) 1.2 (1.1 to 1.4) 1.7 (1.4) 1.1 (1.0) 0.7 (0.5 to 0.8)
*Adjusted for categorical age (5- year interval).
KYH, Know Your Heart.
Table 3 ORs for having at least one plaque per 1 SD increase in each adiposity measure: pooled results from the two studies
Model 1 OR (95% CI) P value Model 2 OR (95% CI) P value Model 3 OR (95% CI) P value
Men (n=2200)
  st BMI 1.12 (1.02 to 1.23) 0.02 1.13 (1.03 to 1.24) 0.01 1.01 (0.91 to 1.12) 0.83
  st WHR 1.21 (1.08 to 1.34) 0.001 1.18 (1.06 to 1.31) 0.003 1.05 (0.93 to 1.18) 0.46
Women (n=2862)
  st BMI 1.06 (0.99 to 1.14) 0.08 1.06 (0.99 to 1.13) 0.09 0.94 (0.87 to 1.01) 0.08
  st WHR 1.20 (1.11 to 1.30) <0.001 1.15 (1.06 to 1.25) 0.001 1.00 (0.91 to 1.09) 0.94
Model 1: adjusted for categorical age (5 years) and study, model 2: adjust for variables in model 1 plus potential confounders (smoking and 
education), model 3: adjusted for variables in model 2 plus potential mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, 
glycated haemoglobin, medical history of diabetes).
HDL, high- density lipoprotein; LDL, low- density lipoprotein; St BMI, body mass index z- score; st WHR, waist- to- hip ratio z- score.
between-study differences in carotid plaque burden and the 
effect of adiposity
Figure 1 compares the carotid plaque burden between 
the two studies with and without adjustment for adiposity. 
Without adjustment for adiposity measures, the OR for 
having at least one plaque in KYH compared with Tromsø 
7 was 1.97 (95% CI 1.62 to 2.38) in women and 2.78 (95% 
CI 2.21 to 3.49) in men (figure 1A, online supplementary 
table 2A model 2). Further adjustment for BMI or WHR 
separately had only a small effect on this OR for both men 
and women (figure 1A). The between- study difference 
remained large and statistically significant after further 
adjustment for cardiometabolic mediators (figure 1A, 
online supplementary table 2A model 3).
Similarly, without adjustment for adiposity, partici-
pants in KYH had a higher mean plaque score than those 
in Tromsø 7 by 0.51 (95% CI 0.42 to 0.60) for women 
and 0.89 (95% CI 0.77 to 1.00) for men; these estimates 
decreased slightly for women and hardly changed at all 
for men with further adjustment for adiposity (figure 1B, 
online supplementary table 2B). The between- study 
difference remained significant after further adjustment 
for cardiometabolic mediators (figure 1B, online supple-
mentary table 2B model 3).
DIsCussIOn
There was evidence of positive associations between 
adiposity, especially abdominal adiposity, and carotid 
plaque burden, but no convincing evidence that the 
strength of these associations differed between the two 
studies. These associations were largely mediated by 
cardio- metabolic CVD risk factors. However, neither 
adiposity nor the confounders and potential mediators 
explained the substantially greater burden of plaque in 
the KYH study in Russia compared with the Tromsø 7 
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Table 4 Difference in plaque score per 1 SD increase in each adiposity measure: pooled results from the two studies
Model 1 slope (95% CI) P value Model 2 slope (95% CI) P value Model 3 slope (95% CI) P value
Men (n=2200)
  st BMI −0.021 (−0.069 to 0.026) 0.38 −0.008 (−0.055 to 0.039) 0.74 −0.091 (−0.143 to −0.040) <0.001
  st WHR 0.033 (−0.025 to 0.090) 0.26 0.013 (−0.043 to 0.069) 0.65 −0.076 (−0.136 to −0.015) 0.01
Women (n=2862)
  st BMI 0.023 (−0.009 to 0.056) 0.16 0.023 (−0.010 to 0.055) 0.17 −0.056 (−0.091 to −0.021) 0.002
  st WHR 0.131 (0.093 to 0.169) <0.001 0.109 (0.070 to 0.147) <0.001 0.025 (−0.018 to 0.067) 0.25
Model 1: adjusted for categorical age (5 years) and study, model 2: adjust for variables in model 1 plus potential confounders (smoking and 
education), model 3: adjusted for variables in model 2 plus potential mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, 
glycated haemoglobin, medical history of diabetes.
HDL, high- density lipoprotein; LDL, low- density lipoprotein; St BMI, body mass index z- score; st WHR, waist- to- hip ratio z- score.
Figure 1 (A) ORs (95% CI) for having at least one plaque 
in KYH versus Tromsø 7 with and without adjustment for 
adiposity. (B) Differences (95% CI) in the mean plaque 
score in KYH compared with Tromsø 7 with and without 
adjustment for adiposity. Confounders: smoking and 
education, mediators: systolic blood pressure, HDL 
cholesterol, LDL cholesterol, glycated haemoglobin, medical 
history of diabetes. BMI, body mass index; HDL, high- 
density lipoprotein; KYH, Know Your Heart; LDL, low- density 
lipoprotein; WHR, waist- to- hip ratio.
study in Norway. To the best of our knowledge, this is the 
first study to directly investigate the role of adiposity in 
high CVD burden in a general population in Russia in 
comparison with another country.
Given the similar adiposity level between KYH and 
Tromsø 7 among men, it is not surprising that higher 
plaque burden in men in KYH is not explained by 
adiposity. However, even among women whose adiposity 
level was considerably higher in KYH than Tromsø 7, 
the adjustment for adiposity had little impact on the 
interstudy difference in carotid plaque burden. Further-
more, additional adjustment for CVD and metabolic risk 
factors such as smoking, SBP and cholesterol level slightly 
reduced this interstudy difference, but the between- 
study difference remained for both men and women, 
suggesting that there are other determinants of higher 
carotid plaque burden in a population in KYH. This is 
consistent with previous studies conducted 20 or more 
years ago, showing that differences in traditional CVD 
risk factors did not fully explain the high CVD burden 
in Russia compared with Western European countries.5 6 
More advanced subclinical atherosclerosis in participants 
in KYH compared with Tromsø 7 is in keeping with the 
higher CVD mortality rate in Russia than Western Euro-
pean countries.4 21
The development of coronary artery disease and athero-
sclerotic plaque is a gradual process that occurs across the 
life course.22 The extent to which single cross- sectional 
measurements of risk factors such as blood pressure and 
smoking can capture the full impact of these risk factors 
on the burden of carotid plaque is therefore question-
able. In making the sort of comparisons between popula-
tions that are the focus of this paper, therefore, it could 
be that we are underestimating the potential contribu-
tion of these risk factors to differences in plaque burden, 
particularly if risk factor profiles have been changing.
One potential determinant of high CVD risk in Russia 
that we have not included is alcohol which has been 
shown to be related to mortality from CVD.23 Vikhireva et 
al added hazardous alcohol consumption to the high- risk 
version of Systematic COronary Risk Evaluation (SCORE) 
to see whether this modified model improved prognostic 
performance of SCORE for future CVD events in the 
Russian population. However, this modification did not 
improve the prediction of CVD events24 although the 
study had limited follow- up and relatively small numbers 
7Imahori Y, et al. BMJ Open 2020;10:e036583. doi:10.1136/bmjopen-2019-036583
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of events. Moreover, it excluded as an outcome alco-
holic cardiomyopathy that contributes to the high CVD 
mortality in Russia25 involving processes other than 
atherosclerosis.26 Differences in treatment and access to 
the medical facilities between Western Europe and Russia 
is likely to partly account for the higher CVD mortality 
rates in Russia, but it is unlikely that differences in treat-
ment could account for the differences in subclinical 
atherosclerosis in a population- based samples. Further-
more, the treatment and access to appropriate medical 
care have been improving rapidly in Russia, especially in 
large cities, so this is likely to be a less important factor 
in the future.27 28 Identification of the determinant(s) 
of advanced subclinical atherosclerosis in Russia will be 
important to target interventions to reduce CVD burden.
There was evidence of positive associations between 
adiposity and plaque burden in both studies emphasising 
the importance of the control of adiposity, especially 
abdominal adiposity, to curb the CVD burden in both 
countries. The prevalence of obesity in Russia has been 
increasing,7 with the notably high level among women 
being of particular concern.7 Another important impli-
cation of our findings is the importance of the control 
of cardiovascular and cardiometabolic mediators. The 
associations between adiposity and carotid plaque 
burden were largely mediated by SBP, cholesterol level 
and HbA1c. The effective control of these traditional risk 
factors will mitigate the negative effect of adiposity.
This study is the first, to our knowledge, to bring together 
data from a high and relatively low CVD mortality country 
to investigate the association of adiposity with carotid 
plaque, and also the extent to which this can explain 
differences in the burden of carotid plaque between the 
two populations. Moreover, this was done using ultra-
sound examination protocols that were aligned between 
the two studies. No previous studies have compared 
imaging of atherosclerotic changes in general popula-
tions between Russia and Western countries. However, 
our investigation has some limitations. First, the anthro-
pometric measures we used are crude measures of visceral 
adiposity. However, estimation of visceral adipose tissue 
using MRI and CT is resource demanding and logistically 
difficult in large epidemiological studies. Second, WC was 
measured differently between the two studies. Although 
the conversion of WC was made using a conversion equa-
tion, this did not allow for individual variability. Stan-
dardisation of the protocol of WC measurement would 
be important in future studies. Third, we did not include 
alcohol in our regression models, although it is likely to 
play an important role in CVD mortality in Russia.29–32 
This is because alcohol consumption in the two study 
populations was not directly comparable. Finally, as 
always, caution must be exercised in generalising to the 
national situation the results we have obtained from the 
two cross- sectional studies of selected groups in two cities 
in Russian and one in Norway city.
Overall, our findings have two implications with respect 
to tackling the high CVD burden in Russia. First, although 
adiposity failed to explain higher plaque burden in Russia 
compared with Norway, adiposity, especially abdominal 
adiposity, appeared to contribute to an increase in carotid 
plaque burden through cardiometabolic mediators such 
as blood pressure and cholesterol. The reduction of 
adiposity level will be important to avoid further CVD 
burden in addition to the control of cardiometabolic 
mediators. Second, our findings suggest that there are 
other unidentified risk factors that determine the higher 
carotid plaque burden in Russia compared with Norway. 
Further studies will be needed to identify them.
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